XNW5004
XNW5004 is an experimental small-molecule drug from Evopoint Biosciences in phase 2 trials for follicular lymphoma and prostate cancer, aimed at EZH2.
Overview
XNW5004 is a small-molecule drug developed by Evopoint Biosciences. Its target is EZH2. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in follicular lymphoma and prostate cancer. The largest, NCT06702995, plans to enrol 307 participants with primary completion expected 2026-05-13. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"XNW5004" OR ABSTRACT:"XNW5004" OR TITLE:"EZH2i" OR ABSTRACT:"EZH2i") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about XNW5004, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentTC011
Shares Follicular lymphoma and the tags pipeline, ctgov-ingest.
- TreatmentCRC01
Shares Follicular lymphoma and the tags pipeline, ctgov-ingest.
- TreatmentCTX112
Shares Follicular lymphoma and the tags pipeline, ctgov-ingest.
- TreatmentAZD6621
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentAZD9750
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentFPI-2265
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentQLH12016
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentAbexinostat
Shares Follicular lymphoma and the tags pipeline, ctgov-ingest.